linjc16/ctgov huggingface dataset:
Description of the Organizational Measures Framing Surgery for Idiopathic Scoliosis in Children and Adolescents - Practice Survey

Study Overview
=================
Brief Summary
-----------------
The pediatric orthopaedic surgeon treats idiopathic scoliosis in children and adolescents using the posterior vertebral arthrodesis technique. This surgery is considered heavy by the child and families while it is intended for a healthy population. Through this study to take stock of the measures governing idiopathic scoliosis surgery (pre-operative, intra-operative and post-operative) within the various pediatric orthopedic surgery departments on the French national territory.

Detailed Description
-----------------
The goal is to measure the interest of harmonizing the preparation of orthopedic surgery for idiopathic scoliosis in children and adolescents by implementing a ERAS (Enhanced Rehabilitation After Surgery) protocol nationwide.

Official Title
-----------------
Description of the Organizational Measures Framing Surgery for Idiopathic Scoliosis in Children and Adolescents - Practice Survey

Conditions
-----------------
Practice Scope

Intervention / Treatment
-----------------
* Other: questionnaire on the organizational management


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Paediatric orthopaedic surgeons in the national territory who routinely treat idiopathic scoliosis in children and adolescents and who are members of the Société Française d'Orthopédie Pédiatrique (SoFOP) Exclusion Criteria: Refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| paediatric orthopaedic surgeons<br>paediatric orthopaedic surgeons in the national territory who routinely treat idiopathic scoliosis in children and adolescents and who are members of the Société Française d'Orthopédie Pédiatrique (SoFOP) will be included. questionnaire will be completed. . | Other: questionnaire on the organizational management<br>* Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| practices currently in force for the preparation of posterior vertebral arthrodesis | Analysis practices currently in force for the preparation of posterior vertebral arthrodesis by intern results questionnaires. questionnaire is created by the department specifically for this study | Month: 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric orthopaedic surgeon, Idiopathic Scoliosis, Pediatric, Enhanced Rehabilitation After Surgery (ERAS), posterior vertebral arthrodesis
Retroversion in Reverse Shoulder Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to compare function in reverse shoulder arthroplasty (RSA) using two different degrees of humeral retroversion (RV). The main question it aims to answer is: • Does external rotation improves when using a higher retroversion? Participants will randomly receive a 0 degree or 30 degree RV for their RSA. They will be followed for two years and clinical outcomes will be recorded and analyzed.

Official Title
-----------------
In a Reverse Shoulder Arthroplasty, Does Function Depend on the Humeral Version? A Prospective Randomized Study.

Conditions
-----------------
Shoulder Osteoarthritis

Intervention / Treatment
-----------------
* Device: Reverse shoulder arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients > 60 years primary rotator cuff arthropathy implantation of reverse shoulder arthroplasty Exclusion Criteria: previous surgeries in the shoulder post-traumatic arthropathy

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RSA-RV-30<br> | Device: Reverse shoulder arthroplasty<br>* Reverse shoulder arthroplasty<br>|
| Experimental: RSA-RV-0<br> | Device: Reverse shoulder arthroplasty<br>* Reverse shoulder arthroplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| External rotation of the shoulder | External rotation of the shoulder will be measured in degrees with the help of a goniometer in two ways. First: External rotation 1 (ER1): arm adducted at zero degrees Second: External rotation 2 (ER2): arm in 90 degrees of abduction. | 2 years | 
| Constant-Murley Score | The Constant-Murley score is a multi-item functional scale assessing pain, daily activities, range of motion and strength of the affected shoulder. Its score ranges from 0 to 100 points, representing worst and best shoulder function, respectively | 2 years |
Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

Study Overview
=================
Brief Summary
-----------------
The goal of this patient registry is to describe risk factors for bad prognosis of melanoma in Spain. The main questions it aims to answer are: To describe socioeconomical individual risk factors associated with melanoma prognosis, such as gender, residence area or socioeconomic level. To describe potentially modifiable characteristics of health care associated with prognosis, such as waiting times, type of centre that makes the diagnosis or use of teledermatology Participants data will be gathered for analysis, without any change in the way that they are being treated.

Official Title
-----------------
Registro de Melanoma de la AEDV

Conditions
-----------------
Melanoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres. Exclusion Criteria: In-situ melanomas non-cutaneous melanomas, metastatic melanoma with unknown primary site.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AJCC (American Joint Committee on Cancer) TNM stage (Tumor, node, metastasis) | Staging based on tumor thickness and ulceration, spread to lymph nodes and spread to distant sites. | 1 day At diagnosis | 
| Breslow thickness | Breslow thickness is the measurement of the depth of the melanoma from the surface of your skin down through to the deepest point of the tumour. | 1 day At diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to progression |  | through study completion, an average of 3 years | 
| Survival |  | through study completion, an average of 3 years |
Multiparametric Protocol for Assessment of Intraprocedural Result of MITRACLIP Procedure

Study Overview
=================
Brief Summary
-----------------
Quantification of residual mitral regurgitation (MR) after MitraClip may be challenging. Quantitative methods for severity assessment may be inaccurate and recent recommendations suggest an assessment of changes in both hemodynamic and echocardiographic parameters, but an established prospectively validated approach is still lacking.

Official Title
-----------------
Multiparametric Protocol for Assessment of Intraprocedural Result of MITRACLIP Procedure

Conditions
-----------------
Residual Mitral Regurgitation

Intervention / Treatment
-----------------
* Diagnostic Test: Echocardiographic assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with either degenerative or functional, severe or moderate to severe mitral regurgitation (MR) undergoing percutaneous edge-to-edge repair at San Raffaele Hospital from April 2019. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Echocardiographic assessment|Echocardiographic and hemodynamics assessment of Mitraclip results|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of multiparametric assessment of mitral regurgitation ofter Mitraclip |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MitraClip, Residual Mitral Regurgitation, Mitral Insufficiency
Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)

Study Overview
=================
Brief Summary
-----------------
This study is a cross-sectional study to evaluate accuracy of high-risk DNA-HPV testing using HPV Diagnostic Kit (Bio Farma) compared to Standard Kit (COBAS® 6800 HPV from Roche Molecular Systems) RT-PCR based in urine and cervical swab specimens.

Official Title
-----------------
Detection of High-Risk Human Papilloma Virus in Urine and Cervical Swab Specimens; Comparison Between HPV Diagnostic Kit (Bio Farma) and COBAS 6800 HPV (Roche Molecular Systems)

Conditions
-----------------
Human Papilloma Virus Infection

Intervention / Treatment
-----------------
* Diagnostic Test: HPV Diagnostic Kit (Bio Farma)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sexually active female aged 20-50 years Willing to participate in study and signed the informed consent form. Exclusion Criteria: Pregnant women History of HIV infection On menstruation period History of complete HPV vaccination

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Urine Specimen<br> | Diagnostic Test: HPV Diagnostic Kit (Bio Farma)<br>* Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.<br>* Other names: COBAS 6800 HPV from Roche Molecular Systems;|
| Experimental: Cervical Swab Specimen<br> | Diagnostic Test: HPV Diagnostic Kit (Bio Farma)<br>* Urine samples (30 ml): collected from each subjects using urine pot. Cervical swab: collected from each subject using cyto brush and stored in special container which preservatives fluid.<br>* Other names: COBAS 6800 HPV from Roche Molecular Systems;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance of HPV Diagnostic Kit (Bio Farma) using urine and cervical swab sample | Sensitivity and Specificity of HPV Diagnostic Kita (Bio Farma) | 0 days |
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

Study Overview
=================
Brief Summary
-----------------
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Official Title
-----------------
Analysis of the Efficacy and Tolerance of Covid-19 Convalescent Plasma and Monoclonal Antibodies in the Treatment of SARS-Cov2 Infections in Immunocompromised Patients

Conditions
-----------------
COVID-19 Convalescent Plasma Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.) Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes. Exclusion criteria: Subject who expressed their opposition to participating in the study Subject under guardianship, curatorship or safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of the tolerance of Covid-19 convalescent plasma and monoclonal antibodies in the treatment of SARS-Cov2 infections in immunocompromised patients | This is a retrospective study on patient data from medical records from February 25, 2020 to January 15, 2023 | Files analysed retrospectively from February 25, 2020 to January 15, 2023 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, SARS-Cov2, Immunosuppression, Cytokine, Convalescent Plasma, Monoclonal, Antibodies
Anovo™ Surgical System - Registry Study

Study Overview
=================
Brief Summary
-----------------
To collect Real-World Data (RWD) on the ongoing safety and effectiveness of the anovo Surgical system in transvaginal gynecological laparoscopic surgical procedures and to obtain information on the impact of the anovo Skills Development Pathway on user behavior and performance (where performance is measured by the learning curve of the surgeons and procedure outcomes).

Detailed Description
-----------------
Specific Aims: To collect RWD from surgeons with varying experience and expertise on their learning curve and time to achieve competency, and as such assess the success of the Skills Development Pathway. Collect safety information and analyze the causality between type and frequency of adverse events to surgeons' experience. Evaluate the effectiveness of the device while minimizing bias by enrolling all comers, which will represent the general patient population.

Official Title
-----------------
Anovo™ Surgical System - Registry Study

Conditions
-----------------
GYN Disorders

Intervention / Treatment
-----------------
* Device: anovo™ Surgical System


Participation Criteria
=================
Eligibility Criteria
-----------------
All patients receiving gynecological surgical procedure with the anovo Surgical System by their surgeon will be offered to participate in the registry. Inclusion Criteria: patients must understand and sign the informed consent form, including data privacy authorization, indicating their consent to participate in the registry study. willing to complete post-operative questionnaire Exclusion Criteria: -none
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing gynecological surgical procedure with the anovo Surgical System<br> | Device: anovo™ Surgical System<br>* The anovo Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS during single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Conversion rate to open or laparoscopic approach |  | Procedure | 
| Rate of Unanticipated Adverse Device Effect |  | 8 Weeks Follow Up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgery time (minutes) |  | Procedure |
Relationship Between Acoustic Breath Sounds and Spirometry

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to assess whether wheeze as assessed by a commercially available wheeze monitor is comparable to lung function as measured during a spirometry test. The main questions it aims to answer are whether measures of airflow obstruction (FEV1, FEV1/FVC, PEF) correlate with wheeze score (Tw/Ttot%). Participants consenting to take part will undergo wheeze measurement prior to and during a spirometry test and will be asked to complete a series of symptom questionnaires.

Official Title
-----------------
A Comparative Single Centre Study Assessing the Relationship Between Acoustic Breath Sounds as Measured by a Commercially Available Sound Recording Device Against Standard of Care (Spirometry) in the Assessment of Airflow Obstruction in Patients Who Plan to Undergo Spirometry Testing

Conditions
-----------------
Asthma COPD

Intervention / Treatment
-----------------
* Device: Wheeze measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consenting adult (aged 18-95) University Hospitals Birmingham patient's attending the Lung Function and Sleep Department (LF&S) routinely as part of their standard clinical management pathway for Lung Function testing that includes Spirometry assessments. All patients irrespective of condition will be approached to participate. Exclusion Criteria: Subjects who are contraindicated to perform spirometry on the day of testing Subjects who cannot speak or read English Patients accessing non-adult services Subjects who are unable or do not wish to consent Patients with known or suspected restrictive lung disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All participants<br>Participants will undergo wheeze monitoring during tidal breathing prior to spirometry and during a spirometry test. | Device: Wheeze measurement<br>* Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wheeze score (Tw/Ttot%) | The average proportion of each breath that contained wheeze during a 30 second breath sound recording. | Day 1 | 
| FEV1/FVC | the ratio between forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) | Day 1 | 
| FEV1 |  | Day 1 |
AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Study Overview
=================
Brief Summary
-----------------
In recent years, the introduction of PET/CT tomographs (which have now almost completely replaced tomographs equipped with PET alone), has allowed a significant increase in diagnostic accuracy in the majority of tumors. However, in order to reduce the radiation doses, administering CT images are acquired for patients at a low dose (generally 60mA 120kV) without the use of contrast agents. This prudential attitude, however, makes it essential to carry out diagnostic CT investigations which, at the end of the diagnostic process It leads to an increase in the dose administered for the patient rather than to savings. This study aims to evaluate the possible advantages in diagnostic, economic and quality of life terms of PET/CT performed with diagnostic CT with intravenous contrast medium, with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing (from a temporal and dosimetric point of view ) the diagnostic procedures to which it is subjected. It is expected that the integrated PET/CT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patient's quality of life while also reducing the costs incurred in terms of time and money.

Official Title
-----------------
AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic accuracy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Established lymphoma (non-Hodgkin's lymphoma and Hodgkin's disease) being staged; Performing the PET/CT examination within two weeks of diagnosis and before treatment; Signing of the Informed Consent. Exclusion Criteria: patients <18 years; Patients who have not signed the Informed Consent; Execution of previous anti-inflammatory or anti-inflammatory therapies in the 4 weeks preceding the PET exam.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Diagnostic accuracy|As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET/CT with contrast medium in a single session to diagnosis of patients with malignant limphoma. |  | 2 years |